Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, 93-338 Lodz, Poland.
Department of Endocrinology and Metabolic Diseases, Polish Mother's Memorial Hospital-Research Institute, 93-338 Lodz, Poland.
Int J Environ Res Public Health. 2020 Jul 2;17(13):4756. doi: 10.3390/ijerph17134756.
Depression and osteoporosis are severe public health problems. There are conflicting findings regarding the influence of depression on bone metabolism. The aim of the presented study was to compare bone turnover markers and vitamin D levels between patients treated for depression and healthy controls.
We determined a concentration of osteocalcin, carboxy-terminal telopeptide of type I collagen (β-CTX), 25-hydroxyvitamin D (25OHD) and 1,25(OH)D in 99 patients, aged 46.9 ± 11 years, treated for depression, as well as in 45 healthy subjects. Depressive status was determined with the Hamilton Depression Scale (HDRS).
In patients treated for depression, we demonstrated significantly lower osteocalcin concentrations ( < 0.03) and higher concentration of β-CTX (result on the border of significance; = 0.08). Those relationship were stronger in women. The level of 25OHD and 1,25(OH)D did not differ significantly between the examined groups. We observed a negative correlation between the 25OHD and HDRS score after treatment in all patients treated for depression and in subgroups of women and subjects with recurrent depression.
Our results indicate that depression is related to disturbances in bone metabolism, especially in women and patients with recurrent depression, suggesting its role in context of osteoporosis development.
抑郁和骨质疏松是严重的公共健康问题。关于抑郁对骨代谢的影响，研究结果相互矛盾。本研究旨在比较接受抑郁症治疗的患者和健康对照组之间的骨转换标志物和维生素 D 水平。
我们测定了 99 名年龄为 46.9 ± 11 岁的接受抑郁症治疗的患者和 45 名健康受试者的骨钙素、I 型胶原羧基末端肽（β-CTX）、25-羟维生素 D（25OHD）和 1,25-二羟维生素 D（1,25（OH）2D）的浓度。抑郁状态采用汉密尔顿抑郁量表（HDRS）确定。
在接受抑郁症治疗的患者中，我们发现骨钙素浓度明显降低（<0.03），β-CTX 浓度升高（结果接近显著；=0.08）。这些关系在女性中更强。两组间 25OHD 和 1,25（OH）2D 水平无显著差异。我们观察到所有接受抑郁症治疗的患者以及女性和复发性抑郁症患者亚组中，25OHD 和治疗后 HDRS 评分之间存在负相关。
我们的结果表明，抑郁与骨代谢紊乱有关，尤其是在女性和复发性抑郁症患者中，提示其在骨质疏松症发展中的作用。
